| 000 | 01750 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250518022121.0 | ||
| 264 | 0 | _c20200618 | |
| 008 | 202006s 0 0 eng d | ||
| 022 | _a1468-330X | ||
| 024 | 7 |
_a10.1136/jnnp-2018-319713 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAmmoun, Sylwia | |
| 245 | 0 | 0 |
_aPhase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2. _h[electronic resource] |
| 260 |
_bJournal of neurology, neurosurgery, and psychiatry _c10 2019 |
||
| 300 |
_a1184-1187 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xmetabolism |
| 650 | 0 | 4 | _aBlotting, Western |
| 650 | 0 | 4 |
_aCaspase 3 _xdrug effects |
| 650 | 0 | 4 |
_aCyclin D1 _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 |
_aLeukocytes, Mononuclear _xdrug effects |
| 650 | 0 | 4 |
_aMitogen-Activated Protein Kinase 1 _xdrug effects |
| 650 | 0 | 4 |
_aMitogen-Activated Protein Kinase 3 _xdrug effects |
| 650 | 0 | 4 | _aMolecular Targeted Therapy |
| 650 | 0 | 4 |
_aNeurofibromatosis 2 _xdrug therapy |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-akt _xdrug effects |
| 650 | 0 | 4 |
_aReceptor, Platelet-Derived Growth Factor beta _xdrug effects |
| 650 | 0 | 4 |
_aRibosomal Protein S6 _xdrug effects |
| 650 | 0 | 4 |
_aSorafenib _xmetabolism |
| 700 | 1 | _aEvans, D Gareth | |
| 700 | 1 | _aHilton, David A | |
| 700 | 1 | _aStreeter, Adam | |
| 700 | 1 | _aHayward, Christopher | |
| 700 | 1 | _aHanemann, C Oliver | |
| 773 | 0 |
_tJournal of neurology, neurosurgery, and psychiatry _gvol. 90 _gno. 10 _gp. 1184-1187 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/jnnp-2018-319713 _zAvailable from publisher's website |
| 999 |
_c29327978 _d29327978 |
||